Amarin Co. plc Company Profile (NASDAQ:AMRN)

About Amarin Co. plc (NASDAQ:AMRN)

Amarin Co. plc logoAmarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AMRN
  • CUSIP: N/A
  • Web:
  • Market Cap: $825.62 million
  • Outstanding Shares: 270,695,000
Average Prices:
  • 50 Day Moving Avg: $3.06
  • 200 Day Moving Avg: $3.16
  • 52 Week Range: $1.80 - $3.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -33.89
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $139.18 million
  • Price / Sales: 5.93
  • Book Value: ($0.20) per share
  • Price / Book: -15.25
  • EBIDTA: ($60,320,000.00)
  • Net Margins: -68.45%
  • Return on Assets: -53.64%
  • Debt-to-Equity Ratio: -9.65%
  • Current Ratio: 2.15%
  • Quick Ratio: 1.88%
  • Average Volume: 1.40 million shs.
  • Beta: 0.88
  • Short Ratio: 3.25

Frequently Asked Questions for Amarin Co. plc (NASDAQ:AMRN)

What is Amarin Co. plc's stock symbol?

Amarin Co. plc trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin Co. plc's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. The business had revenue of $34.60 million for the quarter, compared to the consensus estimate of $37.85 million. The business's revenue was up 35.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.14) earnings per share. View Amarin Co. plc's Earnings History.

Where is Amarin Co. plc's stock going? Where will Amarin Co. plc's stock price be in 2017?

4 analysts have issued twelve-month target prices for Amarin Co. plc's shares. Their predictions range from $5.00 to $10.00. On average, they anticipate Amarin Co. plc's share price to reach $6.50 in the next twelve months. View Analyst Ratings for Amarin Co. plc.

What are analysts saying about Amarin Co. plc stock?

Here are some recent quotes from research analysts about Amarin Co. plc stock:

  • 1. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (5/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reaffirm our OW rating and $6 PT on AMRN. On March 17, Amgen announced data from its Repatha FOURIER outcomes study. Repatha is a new PCSK9 inhibitor that lowers LDL-C levels in conjunction with statin use. The results showed a 15% relative reduction in CV risk, but did not show a benefit in overall death rates from CV causes. We believe these results highlight the value of AMRN's REDUCE-IT outcomes study, which seeks to show reduced relative CV risk by lowering triglyceride levels. Reducing risk by doing more than lowering LDL-C levels remains an important goal, in our view. Vascepa may not only reduce CV risk by lowering triglycerides, but it also offers oral administration, an exceptional safety profile, additional pleiotropic benefits and a cost not viewed as prohibitive. Final results of the REDUCE-IT study are expected in mid-2018." (3/16/2017)

Who are some of Amarin Co. plc's key competitors?

Who owns Amarin Co. plc stock?

Amarin Co. plc's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Oracle Investment Management Inc. (2.49%), OppenheimerFunds Inc. (0.00%), Broadfin Capital LLC (1.05%), FMR LLC (0.00%), Renaissance Technologies LLC (0.00%) and Morgan Stanley (0.00%). View Institutional Ownership Trends for Amarin Co. plc.

Who sold Amarin Co. plc stock? Who is selling Amarin Co. plc stock?

Amarin Co. plc's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Oracle Investment Management Inc., Bank of America Corp DE, Goldman Sachs Group Inc., KCG Holdings Inc., SG Americas Securities LLC, State of New Jersey Common Pension Fund D and ProShare Advisors LLC. View Insider Buying and Selling for Amarin Co. plc.

Who bought Amarin Co. plc stock? Who is buying Amarin Co. plc stock?

Amarin Co. plc's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Point72 Asset Management L.P., Quantitative Investment Management LLC, California Public Employees Retirement System, UBS Group AG, Perkins Capital Management Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Amarin Co. plc.

How do I buy Amarin Co. plc stock?

Shares of Amarin Co. plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Amarin Co. plc stock cost?

One share of Amarin Co. plc stock can currently be purchased for approximately $3.05.

Analyst Ratings

Consensus Ratings for Amarin Co. plc (NASDAQ:AMRN) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.50 (113.11% upside)

Analysts' Ratings History for Amarin Co. plc (NASDAQ:AMRN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2017Jefferies Group LLCSet Price TargetBuy$5.00LowView Rating Details
3/22/2017Cantor FitzgeraldReiterated RatingOverweight$6.00LowView Rating Details
1/24/2017HC WainwrightReiterated RatingBuy$10.00N/AView Rating Details
10/19/2016Citigroup IncInitiated CoverageBuy$5.00N/AView Rating Details
8/11/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformN/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Amarin Co. plc (NASDAQ:AMRN)
Earnings by Quarter for Amarin Co. plc (NASDAQ:AMRN)
Earnings History by Quarter for Amarin Co. plc (NASDAQ:AMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/20173/31/2017($0.07)($0.08)$37.85 million$34.60 millionViewListenView Earnings Details
2/28/201712/31/2016($0.09)($0.05)$36.13 million$38.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.08)$32.03 million$32.40 millionViewN/AView Earnings Details
8/4/2016Q216($0.13)($0.07)$29.97 million$32.82 millionViewN/AView Earnings Details
5/5/2016Q116($0.11)($0.14)$26.77 million$25.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.08)($0.12)$23.62 million$26.40 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.18)$21.93 million$21.30 millionViewN/AView Earnings Details
8/6/2015Q2($0.12)($0.15)$19.10 million$17.70 millionViewN/AView Earnings Details
5/8/2015Q115($0.11)($0.18)$21.86 million$15.60 millionViewN/AView Earnings Details
3/3/2015Q414($0.13)($0.11)$17.40 million$16.50 millionViewN/AView Earnings Details
11/6/2014Q314($0.14)($0.18)$14.87 million$14.15 millionViewN/AView Earnings Details
8/7/2014Q214($0.15)($0.14)$12.86 million$12.60 millionViewN/AView Earnings Details
5/9/2014Q114($0.18)($0.17)$11.65 million$11.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.23)($0.26)$11.17 million$10.10 millionViewN/AView Earnings Details
11/7/2013($0.32)($0.25)$10.25 million$8.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.38)($0.26)$5.50 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.39)($0.41)$5.21 million$2.34 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.28)($0.28)ViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amarin Co. plc (NASDAQ:AMRN)
2017 EPS Consensus Estimate: ($0.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.07)($0.06)($0.07)
Q2 20172($0.08)($0.06)($0.07)
Q3 20172($0.07)($0.05)($0.06)
Q4 20172($0.07)($0.05)($0.06)
(Data provided by Zacks Investment Research)


Dividend History for Amarin Co. plc (NASDAQ:AMRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Amarin Co. plc (NASDAQ:AMRN)
Insider Ownership Percentage: 9.70%
Institutional Ownership Percentage: 39.07%
Insider Trades by Quarter for Amarin Co. plc (NASDAQ:AMRN)
Institutional Ownership by Quarter for Amarin Co. plc (NASDAQ:AMRN)
Insider Trades by Quarter for Amarin Co. plc (NASDAQ:AMRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2016John F TheroCEOBuy25,000$1.37$34,250.00View SEC Filing  
8/11/2015John F TheroCEOBuy20,000$2.35$47,000.00View SEC Filing  
11/12/2014John F TheroInsiderBuy50,000$0.83$41,500.00View SEC Filing  
11/11/2014Michael James FarrellInsiderBuy5,500$0.84$4,620.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amarin Co. plc (NASDAQ:AMRN)
Latest Headlines for Amarin Co. plc (NASDAQ:AMRN)
DateHeadline logoETFs with exposure to Amarin Corp. Plc : May 22, 2017 - May 22 at 3:33 PM logoAmarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care - May 18 at 12:15 PM logoFY2017 Earnings Estimate for Amarin Co. plc Issued By Cantor Fitzgerald (AMRN) - May 12 at 1:20 PM logoETFs with exposure to Amarin Corp. Plc : May 11, 2017 - May 11 at 8:54 PM logoAmarin: Waiting For The Second Interim Analysis Results - May 11 at 3:53 PM logo Analysts Anticipate Amarin Co. plc (AMRN) Will Post Quarterly Sales of $40.07 Million - May 11 at 11:00 AM logoAmarin Corp. Plc :AMRN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 - May 10 at 3:43 PM logo Brokerages Anticipate Amarin Co. plc (AMRN) Will Post Earnings of -$0.07 Per Share - May 9 at 4:32 PM logoAmarin Co. plc (AMRN) Downgraded by Zacks Investment Research to Hold - May 8 at 10:52 PM logoIs the Options Market Predicting a Spike in Amarin Corporation (AMRN) Stock? - May 8 at 11:00 AM logoResearch Analysts Offer Predictions for Amarin Co. plc's Q1 2017 Earnings (AMRN) - May 4 at 8:06 AM logoEdited Transcript of AMRN earnings conference call or presentation 3-May-17 12:00pm GMT - May 3 at 8:36 PM logoAmarin Co. plc (AMRN) Receives Coverage Optimism Score of 0.19 - May 3 at 7:20 PM logoAmarin Co. plc (AMRN) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - May 3 at 12:18 PM logoBRIEF-Amarin Q1 loss per share $0.08 - May 3 at 9:19 AM logoInvestor Calendar Invites You to the Amarin First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, May 3, 2017 - May 3 at 9:19 AM logoAmarin Reports First Quarter 2017 Financial Results and Provides Update on Operations - May 3 at 9:19 AM logoAmarin reports 1Q loss - May 3 at 9:19 AM logoInvestor Network: Amarin Corporation Plc Sponsored ADR to Host Earnings Call - May 3 at 9:19 AM logoAmarin Co. plc (AMRN) Set to Announce Earnings on Wednesday - May 1 at 10:30 AM logoAmarin Co. plc (AMRN) Given News Impact Rating of 0.17 - April 29 at 12:29 PM logoETFs with exposure to Amarin Corp. Plc : April 26, 2017 - April 26 at 3:43 PM logoAmarin to Report First Quarter 2017 Results and Host Conference Call on May 3, 2017 - April 26 at 8:17 AM logoAmarin Co. plc (AMRN) Earns Daily Media Sentiment Score of -0.03 - April 24 at 5:12 PM logoAmarin Co. plc (AMRN) Receives Daily Coverage Optimism Rating of 0.02 - April 20 at 2:35 PM logo$36.1 Million in Sales Expected for Amarin Co. plc (AMRN) This Quarter - April 20 at 11:29 AM logo Analysts Anticipate Amarin Co. plc (AMRN) Will Post Earnings of -$0.07 Per Share - April 18 at 8:26 PM logoAmarin Co. plc (AMRN) Given Media Sentiment Score of 0.56 - April 15 at 8:24 AM logoJefferies Group LLC Reiterates $5.00 Price Target for Amarin Co. plc (AMRN) - April 7 at 11:24 PM logoETFs with exposure to Amarin Corp. Plc : April 7, 2017 - April 7 at 8:34 PM logoAmarin Co. plc (AMRN) Stock Rating Upgraded by Zacks Investment Research - April 3 at 10:03 PM logo3 Stocks That Could Make You Rich - April 3 at 1:29 AM logoAMARIN CORP PLC\UK Files SEC form 8-K, Shareholder Director Nominations - March 28 at 9:31 AM logoAmarin Co. plc's (AMRN) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - March 28 at 8:47 AM logoAmarin Co. plc's (AMRN) Overweight Rating Reiterated at Cantor Fitzgerald - March 22 at 10:34 AM logoAmarin Corporation CEO, John Thero, to Chair the American Heart Association’s Heart & Stroke Ball in New York City - March 21 at 3:53 PM logoAmarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study - March 16 at 5:01 PM logoAmarin Corp. (AMRN) Publishes REDUCE-IT Cardiovascular ... - - March 15 at 3:41 PM logoAmarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology - March 15 at 3:41 PM logo10:01 am Amarin announces the publication of the rationale and design for the company's REDUCE-IT Phase 3 cardiovascular outcomes study in Clinical Cardiology - March 15 at 3:41 PM logoAMARIN CORP PLC\UK Financials - March 8 at 3:34 PM logoHere's What Pushed Amarin Corporation plc 15% Higher in February - March 6 at 3:30 PM logoAMARIN CORP PLC\UK Files SEC form 10-K, Annual Report - March 1 at 8:30 PM logoAmarin Corporation (AMRN) Flat on Q4 Loss - February 28 at 3:36 PM logoAmarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations - February 28 at 9:14 AM logo6:05 am Amarin misses by $0.02, beats on revs - February 28 at 9:14 AM logoAMARIN CORP PLC\UK Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi - February 28 at 9:14 AM logoQ4 2016 Amarin Corporation PLC Earnings Release - Before Market Open - February 28 at 9:14 AM logoInteresting AMRN Call Options For May 19th - - February 22 at 8:32 PM logoAmarin to Report Fourth Quarter and Full Year 2016 Results and Host Conference Call on February 28th, 2017 - GlobeNewswire (press release) - February 22 at 3:32 PM



Amarin Co. plc (AMRN) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff